BRISTOL-MYERS SQUIBB COMPANY Deferred Revenue and Credits
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Deferred Revenue and Credits of $1.89 billion as of 2016-09-30, per its 10-Q filed 2016-10-27.
Discontinued › Notes › ASU 2014-09 Transition
us-gaap:DeferredRevenueAndCredits · last filed 2016-10-27
- 2016-09-30: Deferred Revenue and Credits $1.89B.
- 2016-06-30: Deferred Revenue and Credits $1.77B.
- 2016-03-31: Deferred Revenue and Credits $1.77B.
- 2015-12-31: Deferred Revenue and Credits $1.59B.
| Period end | Deferred Revenue and Credits |
|---|---|
| 2016-09-30 | $1.89B 10-Q · filed 2016-10-27 |
| 2016-06-30 | $1.77B 10-Q · filed 2016-07-28 |
| 2016-03-31 | $1.77B 10-Q · filed 2016-04-28 |
| 2015-12-31 | $1.59B 10-Q · filed 2016-10-27 |
| 2015-09-30 | $1.59B 10-Q · filed 2015-10-27 |
| 2015-06-30 | $1.61B 10-Q · filed 2015-07-23 |
| 2015-03-31 | $2.16B 10-Q · filed 2015-04-28 |
| 2014-12-31 | $1.94B 10-K · filed 2016-02-12 |
| 2014-09-30 | $1.80B 10-Q · filed 2014-10-24 |
| 2014-06-30 | $2.13B 10-Q · filed 2014-07-24 |
| 2014-03-31 | $2.13B 10-Q · filed 2014-04-29 |
| 2013-12-31 | $1.52B 10-K · filed 2015-02-13 |
| 2013-09-30 | $5.20B 10-Q · filed 2013-10-23 |
| 2013-06-30 | $5.13B 10-Q · filed 2013-07-25 |
| 2013-03-31 | $4.87B 10-Q · filed 2013-04-25 |
| 2012-12-31 | $4.85B 10-K · filed 2014-02-14 |
| 2012-09-30 | $4.70B 10-Q · filed 2012-10-24 |
| 2011-12-31 | $1.20B 10-K · filed 2013-02-15 |
| 2010-12-31 | $1.30B 10-K · filed 2012-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |